DEFIBROTIDE (Defibrotide)
DEFITELIO 80 mg/mL
- Medicine Name: Defitelio
API: Defibrotide - Dosage Form & Strength: Injection: 200 mg/2.5 mL (80 mg/mL) in a single-patient-use vial
- Manufactured By: Jazz Pharmaceuticals, Inc.
Defitelio (defibrotide) is used for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).
Recommended Dosage: The recommended dosage of Defibrotide for adult and pediatric patients is 6.25 mg/kg every 6 hours, administered as a 2-hour intravenous (IV) infusion. The dose should be based on the patient’s baseline body weight, defined as the patient’s weight before the preparative regimen for HSCT. Administer this therapeutic drug for a minimum of 21 days. If, after 21 days, signs and symptoms of hepatic VOD have not resolved, continue treatment with this medicine until resolution of VOD or up to a maximum of 60 days.
- Defibrotide 200 mg/2.5 mL (80 mg/mL) treatment increases the likelihood of serious bleeding in patients with active or ongoing bleeding and those already using anticoagulants or antiplatelets. Use caution with invasive procedures. Look for potential signs of bleeding, and if there is a major hemorrhage, treatment should be stopped if it is neither safely nor easily controlled.
- Defibrotide treatment carries the risk of serious hypersensitivity reactions such as rash, swelling, or difficulty in breathing. It should be stopped right away once there are any signs of hypersensitivity. People diagnosed with Defibrotide hypersensitivity, or any of its constituent parts, should not use it. When starting therapy, emergency treatment should be ready in case it is needed.
- Use of Defibrotide in pregnancy should be done only when absolutely necessary. The data on human pregnancy is scarce, while the studies on animals are inadequate. The possible risks posed to the fetus need to be balanced against the benefits. Effective contraceptives should be used during the treatment by women who are capable of childbearing.
- In breastfeeding women, the possibility of Defibrotide being excreted in human milk is not known. If the treatment poses a risk to the infant, there is a need to consider stopping breastfeeding or halting the drug, depending on the importance of the treatment for the mother and potential risks to the infant.
- Defibrotide has been examined with a focus on its safety in children with hepatic veno-occlusive disease. Its safety and effectiveness seem comparable to that demonstrated in adults. Still, dose adjustments and meticulous monitoring with adequate supportive care are vital. Physicians need to observe the child’s condition throughout therapy and combine adaptive treatment as appropriate.
- Clinical experience in older patients 65 years and above is limited. No differences in safety or effectiveness were reported, although some evidence of greater susceptibility in the “older” group cannot be fully excluded. Exercise care in older patients with multiple comorbidities because of high chances of frailty.
What documents are required to import DEFITELIO to India?
DEFITELIO (defibrotide) injections can be imported by patients or government hospitals in the name of the patients only.
The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patient ID proof (issued by the government of India)
How does the order get confirmed?
The order will be confirmed only after the receipt of:
- A valid prescription from the Doctor
- Import permit if applicable
Is DEFITELIO available in India?
Defitelio (defibrotide injections) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input
- On availability of Defitelio in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
- On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
Medicine Price. - Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
Ensuring 100% transparency.
DEFITELIO can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.
IPN (Indian Pharma Network) can facilitate the supply of DEFITELIO (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).
Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Defitelio 200 mg/2.5 mL injection price in India.
We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.
Indian Pharma Network can source DEFITELIO (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
What is the Generic Name for the trade name drug Defitelio®?
Defibrotide is a Generic Name for the trade name drug Defitelio®.
What is the Manufacturer’s Name of Defitelio®?
Defitelio® is manufactured by Jazz Pharmaceuticals, Inc.
Is Defitelio approved by the FDA?
Yes, Defitelio® is approved by the FDA. Date of first approval: March 30, 2016.
What is the dosage and form of Defitelio® supplied?
Defitelio is supplied in Injection: 200 mg/2.5 mL (80 mg/mL) in a single-patient-use vial for intravenous (IV) use.
What are the most common side effects of Defitelio® 200 mg/2.5 mL injections?
The most common side effects of Defitelio® injection are vomiting, hypotension, diarrhea, nausea, and epistaxis.
How much does Defitelio® 200 mg/2.5 mL injection cost in India?
Prices of Defitelio injections may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Defitelio 200 mg/2.5 mL cost in India, please call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.
Can Defitelio® 200 mg/2.5 mL injections be available in SAARC countries?
Apart from Gulf countries, Defitelio® can be available in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Defitelio® injections in these countries. We help ensure legal access to this therapeutic drug through our reliable channels.
Is it safe to buy Defitelio® 200 mg/2.5 mL injections online in India?
Yes, one can buy Defitelio 200 mg/2.5 mL online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the legal supply of Defitelio® injections through legal channels.
What are the storage conditions of Defitelio® 200 mg/2.5 mL injections?
Store defibrotide sodium injection at 20°C to 25°C (68°F to 77°F); excursions permitted between 15 °C to 30°C (59°F to 86°F).
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.